Abstract
Thromboembolism remains a frequent and serious problem in cardiac patients. Methods to identify the thrombosis prone patient and the identification of safe and effective forms of treatment would be of great value.
The accumulating evidence which indicates that abnormalities in platelet tests are often present in cardiac patients and may help identify those at greatest risk of thrombosis is encouraging. It suggests that patients with cardiac disease are desirable groups for investigation. It also indicates that the platelet survival test may be useful as a reference against which new and more practical tests can be compared, as well as a means to identify useful platelet suppressant drugs or to monitor the effects of these drugs.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Genton E, Steele PP: Platelets, drugs and heart disease. In PLATELETS, DRUGS AND THROMBOSIS, edited by Hirsh J, Cade J, Gallus A, Schonbaum E. Basel, Karger, 1975.
Steele PP, Weily HS, Davies H, Genton E: Platelet function studies in coronary artery disease. CIRCULATION 48: 1194–1200, 1973.
Ritchie JL, Harker LA: Platelet and fibrinogen survival in coronary atherosclerosis. AM J CARDIOL 39: 595–598, 1977.
Steele PP, Battock D, Pappas G, Genton E: Correlation of platelet survival time with occlusion of saphenous vein aortocoronary bypass grafts. CIRCULATION 53: 685–687, 1976.
Genton E, Steele PP: Platelet survival: Value for the diagnosis of thromboembolism and evaluation of antithrombotic drugs. PROCEEDINGS OF INT’L. SYMPOSIUM ON PLATELETS AND THROMBOSIS, Milan, 1976. (In Press)
Genton E, Gent M, Hirsh J, Harker LA: Platelet-inhibiting drugs in the prevention of clinical thrombotic disease. N ENGL J MED 293:1174–1178, 1236–1240 and 1296–1300, 1975.
Research Committee of the Scottish Society of Physicians: Ischaemic heart disease: A secondary prevention trial using clofibrate. BR MED J 4: 775–784, 1971.
Group of Physicians of the Newcastle upon Tyne Region: Trial of clofibrate in the treatment of ischaemic heart disease. BR MED J 4:767–775, 1971.
Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381, 1975.
Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R: A randomized controlled trial of acetyl salicyclic acid in the secondary prevention of mortality from myocardial infarction. BR MED J 1: 436–440, 1974.
Coronary Drug Project Research Group: Aspirin in coronary heart disease. J CHRONIC DIS 29: 625–642, 1976.
Breddin K, Uberla K, Walter E: German-Austrian multicenter two-year prospective study on the prevention of secondary myocardial infarction by ASA in comparison to phenprocoumon and placebo. THROMB HAEMOSTAS 38: 168, 1977 (Abstract).
McEnany MT, DeSanctis RW, Harthorne JW, Mundth ED, Weintraub RM, Austen WG, Salzman EW: Effect of antithrombotic therapy on aortocoronary vein graft patency rates. CIRCULATION 54 (Suppl II): 2–124, 1976 (Abstract).
Weily H, Steele PP, Davies H, Pappas H, Genton E: Platelet survival in patients with substitute heart valves. N ENGL J MED 290: 534–537, 1974.
Steele PP, Weily HS, Davies H, Genton E: Platelet survival in patients with rheumatic heart disease. N ENGL J MED 290: 537–539, 1974.
Sullivan JM, Harken DE, Gorlin R: Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N ENGLJ MED 284: 1391–1394, 1971.
Arrants JE, Hairston P: Use of Persantine in preventing thromboembolism following valve replacement. AM SURG 38: 432–435, 1972.
Taguchi K, Matsumura H, Washizu T, et al.: Effect of athrombogenic therapy, especially high dose therapy of dipyridamole, after prosthetic valve replacement. J CARDIOVASC SURG 16: 8–15, 1975.
Altman R, Boullon F, Rouvier J, Raca R, Fuente L, Favaloro R: Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J THORAC CARDIOVASC SURG 72: 127–129, 1976.
Dale J, Myhre E, Storstein O, Stormorken H, Efskind L: Prevention of arterial thromboembolism with acetylsalicyclic acid. AM HEART J 94: 101–111, 1977.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer Science+Business Media New York
About this chapter
Cite this chapter
Genton, E. (1978). Cardiac Thromboembolism: Evidence for Role of Platelets and Value of Platelet Suppressant Therapy. In: Day, H.J., Molony, B.A., Nishizawa, E.E., Rynbrandt, R.H. (eds) Thrombosis. Advances in Experimental Medicine and Biology, vol 102. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1217-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1217-9_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1219-3
Online ISBN: 978-1-4757-1217-9
eBook Packages: Springer Book Archive